Fundraising Fox
/Companies
Sign in

ジェイファーマ株式会社

Tokyo, JP · 7 known investors

Find your way into ジェイファーマ株式会社

Sign up to see every warm intro you have to ジェイファーマ株式会社

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the ジェイファーマ株式会社 team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

J-Pharma is a drug development company focused on SLC transporter-targeted therapies, with its lead LAT1 inhibitor nanvuranlat (JPH203) in a global Phase 3 trial for biliary tract cancer and other candidates addressing cancer, autoimmune, and rare diseases. The Tokyo-based biotech develops innovative small-molecule drugs and is listed on the Tokyo Stock Exchange Growth Market.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

�益𠮷武 益広
𠮷武 益広代表取締役社長 (Representative Director & President)
藤裕藤本 裕
藤本 裕取締役CFO
山寛山本 寛
山本 寛取締役CBO

Investors · 7

KSP, Inc.listed by KSP, Inc.Kawasaki

How we know: KSP, Inc.'s portfolio page · Not right? Tell us

Newton Biocapitallisted by Newton BiocapitalBrussels

How we know: Newton Biocapital's portfolio page · the VCSheet dataset · Not right? Tell us

Oita Venture Capitallisted by Oita Venture CapitalOita
OSAKA University Venture Capitallisted by OSAKA University Venture CapitalOsaka

How we know: OSAKA University Venture Capital's portfolio page · Not right? Tell us

Seibu Shinkin Capitallisted by Seibu Shinkin CapitalTokyo
UntroD Capitallisted by UntroD CapitalTokyo

Related companies · 2

Johnson & JohnsonJohnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision. Its two main businesses, Innovative Medicine and MedTech, focus on treating complex diseases through science-based drugs and less invasive, personalized medical devices.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies working in the same space as ジェイファーマ株式会社.

Frequently asked questions

What does ジェイファーマ株式会社 do?
J-Pharma is a drug development company focused on SLC transporter-targeted therapies, with its lead LAT1 inhibitor nanvuranlat (JPH203) in a global Phase 3 trial for biliary tract cancer and other candidates addressing cancer, autoimmune, and rare diseases. The Tokyo-based biotech develops innovative small-molecule drugs and is listed on the Tokyo Stock Exchange Growth Market.
Who founded ジェイファーマ株式会社?
ジェイファーマ株式会社 was founded by 𠮷武 益広.
Who are ジェイファーマ株式会社's investors?
ジェイファーマ株式会社's investors include F-Prime Capital, KSP, Inc., Newton Biocapital, Oita Venture Capital, OSAKA University Venture Capital, Seibu Shinkin Capital, UntroD Capital.
Where is ジェイファーマ株式会社 headquartered?
ジェイファーマ株式会社 is headquartered in Tokyo, JP.